Blockades of angiotensin and aldosterone reduce osteopontin expression and interstitial fibrosis infiltration in rats with myocardial infarction

Chinese Medical Journal

Volumn 121, Issue 21, 2008, Pages 2192-2196

  Zhang, Yu Ling ^a   Zhou, Shu Xian ^a   Lei, Juan ^a   Yuan, Gui Yi ^a   Wang, Jing Feng ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Myocardial infarction; Osteopontin; Renin angiotensin system

Indexed keywords

OSTEOPONTIN; PERINDOPRIL; SPIRONOLACTONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; HEART HEMODYNAMICS; HEART INFARCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; SYSTOLIC DYSFUNCTION; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; FIBROSIS; HEART MUSCLE; HEMODYNAMICS; PATHOLOGY; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

ALDOSTERONE ANTAGONISTS; ANGIOTENSINS; ANIMALS; FIBROSIS; HEMODYNAMICS; MALE; MYOCARDIAL INFARCTION; MYOCARDIUM; OSTEOPONTIN; RATS; RATS, SPRAGUE-DAWLEY;

EID: 58149360318     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200811010-00016     Document Type: Article

References (33)

1. Anversa P, Beghi C, Kikkawa Y, Olivetti G. Myocardial infarction in rats: infarct size, myocyte hypertrophy, and capillary growth. Circ Res 1986; 58: 26-37.
2. Zhang RY, Wang LF, Zhang L, Meng XN, Li SJ, Wang WR. Effects of angiotensin converting enzyme inhibitor, angiotensin II type I receptor blocker and their combination on postinfarcted ventricular remodeling in rats. Chin Med J 2006; 119: 649-655.
3. Wang D, Liu YH, Yang XP, Rhaleb NE, Xu J, Peterson E, et al. Role of a selective aldosterone blocker in mice with chronic heart failure. J Card Fail 2004; 10: 67-73.
4. Latini R, Staszewsky L, Maggioni AP, Marino P, Hernandez-Bernal F, Tognoni G, et al. Beneficial effects of angiotensin-converting enzyme inhibitor and nitrate association on left ventricular remodeling in patients with large acute myocardial infarction: the Delapril Remodeling after Acute Myocardial Infarction (DRAMI) trial. Am Heart J 2003; 146: 133.
5. Uehara K, Nomura M, Ozaki Y, Fujinaga H, Ikefuji H, Kimura M, et al. High-sensitivity C-reactive protein and left ventricular remodeling in patients with acute myocardial infarction. Heart Vessels 2003; 18: 67-74.
6. Xie Z, Singh M, Singh K. Osteopontin modulates myocardial hypertrophy in response to chronic pressure overload in mice. Hypertension 2004; 44: 826-831.
7. Schellings MW, Pinto YM, Heymans S. Matricellular proteins in the heart: possible role during stress and remodeling. Cardiovasc Res 2004; 64: 24-31.
8. Lou N, Yu XQ, Zhu SL, Zheng XH, Dong XQ, Li XY. Angiotensin II up-regulates osteopontin mRNA expression of RAW264.7 macrophages via p38MAPK signaling. Natl Med J Chin (Chin) 2004; 84:1283-1287.
9. Suezawa C, Kusachi S, Murakami T, Toeda K, Hirohata S, Nakamura K, et al. Time-dependent changes in plasma osteopontin levels in patients with anterior-wall acute myocardial infarction after successful reperfusion: correlation with left-ventricular volume and function. J Lab Clin Med 2005; 145: 33-40.
10. Kusuyama T, Yoshiyama M, Omura T, Nishiya D, Enomoto D, Matsumoto R, et al. Angiotensin blockade inhibits osteopontin expression in non-infarcted myocardium after myocardial infarction. J Pharmacol Sci 2005; 98: 283-289.
11. Iwanaga Y, Hoshijima M, Gu Y, Iwatate M, Dieterle T, Ikeda Y, et al. Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. J Clin Invest 2004; 113: 727-736.
12. Sheehan FH, Bolson EL, Dodge HT, Mathey DG, Schofer J, Woo HW. Advantages and applications of the centerline method for characterizing regional ventricular function. Circulation 1986; 74: 293-305.
13. Lal A, Veinot JP, Ganten D, Leenen FH. Prevention of cardiac remodeling after myocardial infarction in transgenic rats deficient in brain angiotensinogen. J Mol Cell Cardiol 2005; 39: 521-529.
14. Inada T, Fujiwara H, Hasegawa K, Araki M, Yamauchi-Kohno R, Yabana H, et al. Upregulated expression of cardiac endothelin-1 participates in myocardial cell growth in Bio14.6 Syrian cardiomyopathic hamsters. J Am Coll Cardiol 1999; 33: 565-571.
15. Tanaka M, Fujiwara H, Onodera T, Wu DJ, Hamashima Y, Kawai C. Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardiomyopathy. Br Heart J 1986; 55: 575-581.
16. Sodhi CP, Phadke SA, Batlle D, Sahai A. Hypoxia and high glucose cause exaggerated mesangial cell growth and collagen synthesis: role of osteopontin. Am J Physiol Renal Physiol 2001; 280: F667-F674.
17. Graf K, Do YS, Ashizawa N, Meehan WP, Giachelli CM, Marboe CC, et al. Myocardial osteopontin expression is associated with left ventricular hypertrophy. Circulation 1997; 96: 3063-3071.
18. Trueblood NA, Xie Z, Communal C, Sam F, Ngoy S, Liaw L, et al. Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin. Circ Res 2001; 88: 1080-1087.
19. Singh K, Balligand JL, Fischer TA, Smith TW, Kelly RA. Glucocorticoids increase osteopontin expression in cardiac myocytes and microvascular endothelial cells: role in regulation of inducible nitric oxide synthase. J Biol Chem 1995; 270: 28471-28478.
20. Murry CE, Giachelli CM, Schwartz SM, Vracko R. Macrophages express osteopontin during repair of myocardial necrosis. Am J Pathol 1994; 145: 1450-1462.
21. Chandrashekhar Y, Multifunctional role of osteopontin in ventricular remodeling. J Lab Clin Med 2005; 145: 5-8.
22. Pan HT, Zheng QX, Guo XD. Synthetic RGD-containing peptide K16GRGDSPC affected the adhesion, proliferation and osteogenic differentiation of rabbit bone marrow stromal cells on PLGA-[ASP-PEG] scaffold materials. Natl Med J Chin (Chin) 2006; 86: 2766-2770.
23. Nemir M, Bhattacharyya D, Li X, Singh K, Mukherjee AB, Mukherjee BB. Targeted inhibition of osteopontin expression in the mammary gland causes abnormal morphogenesis and lactation deficiency. J Biol Chem 2000; 275: 969-976.
24. Giachelli CM, Lombardi D, Johnson RJ, Murry CE, Almeida M. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am J Pathol 1998; 152: 353-358.
25. Liaw L, Birk DE, Ballas CB, Whitsitt JS, Davidson JM, Hogan BJ. Altered wound healing in mice lacking a functional osteopontin gene (spp1). J Clin Invest 1998; 101: 1468-1478.
26. Somasundaram PE, Chandrashekhar Y. Feasibility of arresting the process of remodeling. Med Clin North Am 2004; 88: 1193-1207.
27. Graf K, Stawowy P. Osteopontin: a protective mediator of cardiac fibrosis? Hypertension 2004; 44: 809-810.
28. Suezawa C, Kuschi S, Mursksmi T, Toeda K, Hirahata S, Nakamura K. Time-dependent changes in plasma osteopontin levels in patients with anterior-wall acute myocardial infarction after successful reperfusion: correlation with left-ventricular volume and function. J Lab Clin Med 2005; 145: 33-40.
29. Sam F, Xie Z, Ooi H, Kerstetter DL, Colucci WS, Singh M, et al. Mice lacking osteopontin exhibit increased left ventricular dilation and reduced fibrosis after aldosterone infusion. Am J Hypertens 2004; 17: 188-193.
30. Ashizawa N, Graf K, Do YS, Nunohiro T, Giachelli CM, Meehan WP, et al. Osteopontin is produced by rat cardiac fibroblasts and mediates A(II)-induced DNA synthesis and collagen gel contraction. J Clin Invest 1996; 98: 2218-2227.
31. Rothermund L, Kreutz R, Kossmehl P, Fredersdorf S, Shakibaei M, Schulze-Tanzil G. Early onset of chondroitin sulfate and osteopontin expression in angiotensin II-dependent left ventricular hypertrophy. Am J Hypertens 2002; 15: 644-652.
32. Collins AR, Schnee J, Wang W, Kim S, Fishbein MC, Bruemmer D, et al. Osteopontin modulates angiotensin II-induced fibrosis in the intact murine heart. J Am Coll Cardiol 2004; 43: 1698-1705.
33. Matsui Y, Jia N, Okamoto H, Kon S, Onozuka H, Akino M, et al. Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy. Hypertension 2004; 43: 1195-1201.